Chairperson’s Perspective: Reframing First-Line and Subsequent Care in Advanced Urothelial Carcinoma – Clinical Implications of the Updated NCCN Guidelines

Chairperson’s Perspective: Reframing First-Line and Subsequent Care in Advanced Urothelial Carcinoma – Clinical Implications of the Updated NCCN Guidelines

June 1, 2026 · 14 min

About this episode

This episode reviews the clinical implications of the updated NCCN Guidelines for advanced urothelial carcinoma, focusing on treatment strategies and patient care.

CME credits: 0.25 Valid until: 01-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/chairpersons-perspective-reframing-first-line-and-subsequent-care-in-advanced-urothelial-carcinoma-clinical-implications-of-the-updated-nccn-guidelines/54396/ This 15-minute online CME activity reviews the clinical implications of the updated NCCN Guidelines for advanced urothelial carcinoma (aUC), with a focus on evolving first-line and subsequent treatment strategies. The program highlights the shift away from cisplatin eligibility as the primary determinant of frontline therapy selection and examines key clinical trial data that inform current practice. Participants will explore sequencing considerations following frontline therapy as well as the role of biomarker-directed therapies in later lines of care. The activity also emphasizes early recognition and management of treatment-related adverse events alongside strategies for dose modification and supportive care. Multidisciplinary coordination and shared decision-making are discussed as essential components of optimizing patient-centered care in aUC. =

People in this episode

Host: Chairperson

Mentioned in this episode

Organizations: NCCN

More episodes of ReachMD CME

Explore listener stats, chart rankings, contacts and more on the ReachMD CME podcast page.